Mirati Therapeutics plans to sell common stock in public offering

Deal will fund research and development, future licensing expenses

By Toni Weeks

San Luis Obispo, Calif., Oct. 3 - Mirati Therapeutics, Inc. plans to sell common shares with a 30-day greenshoe option in a public offering of stock, according to an S-1 filing with the Securities and Exchange Commission.

The company plans to sell shares via joint bookrunners Jefferies LLC and Leerink Swan LLC and lead manager Piper Jaffray & Co.

Proceeds will be used for research and development expenses, working capital, potential future licensing or partnership transactions and other general corporate purchases.

The clinical-stage biopharmaceutical company is based in San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.